Results 91 to 100 of about 827 (180)

New Antibiotics for Lower Respiratory Tract Infections

Microbiology Research
Respiratory tract infections are frequently encountered in clinical practice. The growing incidence of antimicrobial resistance among the causative pathogens exerts sustained pressure on the existing therapeutic options.
Despoina Papageorgiou, Maria Gavatha, Dimitrios Efthymiou, Eleni Polyzou, Aristotelis Tsiakalos, Karolina Akinosoglou   +5 more
doaj   +1 more source

Limited impact of colistin resistance on mortality of intensive care patients with carbapenem-resistant bacteraemia [PDF]

Background Increasing incidence of carbapenem-resistant Gram-negative bacteraemia (CR-GNB) has triggered increased use of polymyxins, likely fuelling the emergence and spread of colistin resistance.
Ioannou, P., Karakonstantis, S., Kofteridis, D., Kokkini, S., Kondili, E., Kritsotakis, E.I., Loukaki, M., Tovil, A., Tryfinopoulou, K., Tziolos, R.-N., Vassilopoulou, L.   +10 more
core   +1 more source

β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development

Pathogens
Antimicrobial resistance remains a public health problem of global concern with a great health and financial burden. Its recognition as a threat by political leadership has boosted the research and development of new antibiotics and particularly novel ...
Angeliki Katsarou, Panagiotis Stathopoulos, Iva D. Tzvetanova, Christina-Maria Asimotou, Matthew E. Falagas   +4 more
doaj   +1 more source

Sulbactam-durlobactam susceptibility among cefiderocol heteroresistant Acinetobacter

The ATTACK clinical trial for treatment of carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) isolates determined treatment with sulbactam-durlobactam to be efficacious and safe.
Bikash Bogati, Tugba Ozturk, Sarah W Satola, David S Weiss   +3 more
openaire   +1 more source

Successful Treatment with Sulbactam-Durlobactam for Severe Acute Pancreatitis Complicated by Extensively Drug-Resistant Acinetobacter baumannii Infection at Multiple Sites: A Case Report

Infection and Drug Resistance
Zhengmao Ge, Li Li, Longxin Wang, Dengke Liu, Yupeng Liu Department of Critical Care Medicine, The 967 Hospital, Joint Logistics Support Force of PLA, Dalian, 116021, People’s Republic of ChinaCorrespondence: Yupeng Liu, Department of Critical Care ...
Ge Z, Li L, Wang L, Liu D, Liu Y
doaj  

Evolution of an extensively antibiotic resistant sublineage of lineage 1 of GC1 Acinetobacter baumannii

npj Antimicrobials and Resistance
The multiply antibiotic-resistant lineage 1 of Acinetobacter baumannii global clone 1 (GC1) emerged in the 1970s, and subsequently more extensively resistant sublineages have emerged.
Christopher J. Harmer, Ting L. Luo, Francois Lebreton, Patrick T. McGann, Ruth M. Hall   +4 more
doaj   +1 more source

The Role of Combination Antibiotic Therapy in Combatting Drug-Resistant Acinetobacter baumannii Infections: A Systematic Review of Randomised Control Trials

Antibiotics
Background: Acinetobacter baumannii is a major global health threat due to its rapid acquisition of multidrug resistance, particularly to carbapenems.
Anteneh Assefa Gezmu, Abel Workalemahu Tesfaye, Anthony R. M. Coates   +2 more
doaj   +1 more source

What do We Know so Far about Ges Carbapenemases, and What Threat do They Pose?

Postępy Mikrobiologii
Carbapenemases, classified as bacterial enzymes, have the ability to hydrolyze carbapenems – important broad-spectrum antibiotics. This work attempts to summarize the information on the diversity of Guiana Extended-Spectrum (GES) subgroup of ...
Rutkowski Kamil, Osnytskyy Anton, Ślifierska Magdalena, Jarząbek Paulina, Bielec Filip, Pastuszak-Lewandoska Dorota, Brauncajs Małgorzata   +6 more
doaj   +1 more source

Susceptibilities of cefiderocol, meropenem-xeruborbactam, cefepime-taniborbactam, aztreonam-avibactam, and sulbactam-durlobactam against imipenem-non-susceptible Gram-negative bacilli in Taiwan

International Journal of Infectious Diseases
Objectives: To evaluate susceptibilities of novel antibiotics against imipenem-non-susceptible (INS) Escherichia coli (INS-EC), Klebsiella pneumoniae (INS-KP), Acinetobacter baumannii (INS-AB), Pseudomonas aeruginosa (INS-PA) in Taiwan, and the potential
Yan-Ru Wang, Yu-Lin Lee, Mei-Chen Tan, Pei-Jing Chen, I-Wen Huang, Jui-Fen Lai, Hui-Ying Wang, Yih-Ru Shiau, Shu-Chen Kuo, Ya-Sung Yang   +9 more
doaj   +1 more source

New antibiotics approved by EMA and FDA (2020–2024): Trends, access in Bulgaria, and implications for antimicrobial resistance control [PDF]

 The aim of the study is to identify trends by analyzing the new antibacterial drugs approved by the EMA and FDA during the period 2020-2024, which can be used for planning antibiotic policies in healthcare institutions providing hospital care.
Ilieva, Mariya
core   +2 more sources